BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Dompe 

Dompe Biogen AG Metallstrasse, 8

6300 - Zug - CH      Switzerland
Phone: 041-7287444 Fax: 041-7287440


SEARCH JOBS










 Company News
Dompe Announces The FDA Has Granted Orphan Drug Designation To Its rhNGF-Based Treatment For Neurotrophic Keratitis 7/23/2014 12:21:27 PM
Pharmaceutical Company Dompe Launches REP0112, a Trial to Assess the Efficacy and Safety of Reparixin in Autologous Islet Cell Transplantation 9/26/2013 10:09:32 AM
Dompe Announces the FDA Has Granted Orphan Drug Designation to Its rhNGF-Based Treatment for Retinitis Pigmentosa 9/11/2013 9:21:59 AM
Dompe Announces Innovative Treatment in the Fight Against Type 1 Diabetes: Pancreatic Islet Cell Transplantation, a Hope That Has Already Come True 7/11/2013 10:14:13 AM
Dompe Announces the European Medicines Agency Has Granted Orphan Drug Designation to Its rhNGF-Based Treatment for Retinitis Pigmentosa 7/1/2013 8:31:07 AM
Dompe Release: The First Patient Has Been Enrolled in the First International Clinical Trial of rhNGF for the Treatment of Neurotrophic Keratitis 2/14/2013 9:52:36 AM
Dompé: The First International Clinical Ophthalmological Trial Concerning Treatment of Neurotrophic Keratitis (NK), an Ocular Pathology With No Cure, Takes Place in Italy 9/7/2012 10:25:56 AM
AAA Acquires Rights to Oncology Antibody Treatment Fabovar from Dompe 8/1/2011 10:02:08 AM
Dyax Corp. (DYAX) Enters into an Exclusive Negotiation Period with Dompe for European License to DX-88 in Angioedema Indications 7/15/2008 6:24:32 AM
Protox Therapeutics Inc. (PRX.V) Announces Manufacturing Agreement with Dompe for PRX321 7/17/2007 3:23:52 PM
12